Cryoport (CYRX)
Runs cryogenic logistics, biostorage, and equipment for life-sciences materials.
Something off on this page? Send us feedback.
Provides temperature-controlled logistics, biostorage, cryopreservation support, software-enabled monitoring, and MVE cryogenic equipment for life-sciences customers. Revenue is split between Life Sciences Services and Life Sciences Products, with demand tied to cell-and-gene therapy trials, approved therapies, biorepository needs, and cryogenic-systems purchases.
Operates a temperature-controlled life-sciences platform across Cryoport Systems, CRYOGENE, and MVE Biological Solutions. Services include BioLogistics, BioStorage/BioServices, cryopreservation support, consulting, packaging, informatics, and monitoring across cryogenic, ultra-cold, refrigerated, and controlled-room-temperature ranges.
The product side is MVE, which sells cryogenic freezers, dewars, dry-vapor shippers, transport systems, and related accessories for life-sciences and animal-health customers. CRYOGENE adds U.S.-based biorepository storage for biological specimens and supplies.
Execution depends on compliance-heavy handling: Cryoportal software, Chain of Compliance, shipper requalification, traceability, and temperature-control expertise. The platform now excludes CRYOPDP after its DHL divestiture, and activity tracks cell-and-gene therapy development, approved therapies, biostorage demand, and cryogenic-equipment cycles.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Needham | Reiterate | Rating: —Target: $15 | Target: $19 |
| Aug 7, 2026 | Guggenheim | Reiterate | Rating: —Target: $12 | Target: $16 |
| Aug 7, 2026 | Roth Capital | Reiterate | Rating: —Target: — | Target: $21 |
| Jul 24, 2026 | BTIG | Reiterate | Rating: —Target: $17 | Target: $25 |
| Jun 8, 2026 | Jefferies | Target | Target: $13 | Target: $13.50 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $396.7M · Total debt $232.0M · Total assets $756.2M · Shareholders' equity $490.7M
- Revenue
- $49.0M
- Operating income
- −$10.0M
- Net income
- −$8.3M
No dividends on record.
| Institutions | ≈ 88.47% | 44.81M shares | |
|---|---|---|---|
| 197 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.53% | 1.79M shares | |
| 8 holders · as of Aug 11, 2026 | |||
| Strategic holders | 15.80% | 8.00M shares | |
| 2 holders · as of Feb 5, 2026 | |||
| Adds to | 107.80% | ||
50.65M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 107.80%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Alger Associates, Inc.Strategic | 9.42% | 4.77M | filed Jan 10, 2022 |
BlackRock, Inc.Institution | 8.33% | 4.22M | as of Jun 30, 2026 |
Integrated Core Strategies (US) LLCStrategic | 6.38% | 3.23M | filed Feb 5, 2026 |
Cadian Capital Management, LPInstitution | 5.77% | 2.92M | as of Jun 30, 2026 |
Morgan StanleyInstitution | 4.50% | 2.28M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 11, 2026 | Jerrell Shelton | director, officer: President, CEO | −28,800 | $14.91 |
| Jun 11, 2026 | Edward J. Zecchini | officer: Chief Digital and Tech Officer | −33,600 | $14.47 |
| Jun 10, 2026 | Edward J. Zecchini | officer: Chief Digital and Tech Officer | −1,400 | $15.23 |
| Jun 8, 2026 | Ramkumar Mandalam | director | −23,214 | $15.44 |
| Jun 4, 2026 | Robert Stefanovich | officer: Chief Financial Officer | −169,427 | $16.27 |
- Thermo Fisher Scientific
Biorepository services, biobanking tools, and cold-chain support
- Azenta
Sample management, biorepositories, and automated cryogenic storage
- Cencora
World Courier CGT logistics and cryogenic storage
- UPS
Healthcare cold chain and Marken clinical-trial logistics
- BioLife Solutions
CGT biopreservation media, cryogenic containers, and thawing tools
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cryoport | $17.71 | +0.48% | $888.1M | — | — | 4.8 | +7.7% |
| Thermo Fisher Scientific | $662.17 | +0.52% | $244.81B | 35.4 | 25.2 | 5.3 | +10.5% |
| Azenta | $34.35 | +1.78% | $1.56B | — | 61.6 | 2.5 | +12.0% |
| Cencora | $315.99 | −0.16% | $61.58B | 23.5 | 16.3 | 0.2 | +5.1% |
| UPS | $95.53 | +0.82% | $80.49B | 17.6 | 12.3 | 0.9 | +7.4% |
| BioLife Solutions | $38.14 | +2.58% | $1.82B | 36.3 | 188.3 | 17.7 | +12.0% |
| Median | 29.5 | 25.2 | 2.5 | +10.5% |